Tonix Pharmaceuticals (NASDAQ:TNXP) stock is soaring 30% in pre-market trading today after the company announced that it had received a patent for the main component of its “monkeypox and smallpox” vaccine. As monkeypox slowly spreads around the world, investors have bid up the stocks of companies that have or are developing vaccines which can be used to prevent the virus.
Earlier today, Tonix announced that it had obtained a patent “covering synthetic horsepox virus.” According to the company, the latter virus “is the basis for the Company’s TNX-801 vaccine in development to protect against monkeypox and smallpox.”
The patent, issued by the United States Patent and Trademark Office (USPTO), is expected to remain valid “until 2037,” Tonix stated.
Tonix’s Recombinant Pox Virus (RPV) platform is also covered by the same patent. The RPV platform is being used to develop vaccines that may prevent people from contracting other deadly diseases. The company’s TNX-1840 and TNX-1850 vaccines are designed to combat Covid-19 and its subvariants by neutralizing the virus’ spike proteins.
In a statement today, Tonix’s CEO, Seth Lederman, said that the company was getting ready “to advance horsepox-based live virus vaccines into clinical development.”
As of May 31, there were reportedly 15 confirmed cases of monkeypox in the U.S. and 584 such cases globally. However, a World Health Organization (WHO) official on Monday said the organization does not expect the outbreak to become a pandemic.
TNXP stock and similar vaccine stocks are expected to see more trading in the days and weeks to come as the monkeypox outbreak plays out.
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
On the date of publication, Larry Ramer did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.